Skip to main content
SpringerLink
Log in

Basis of Therapeutic Nuclear Medicine

  • Chapter
The Pathophysiologic Basis of Nuclear Medicine

  • 1581 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 279.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 359.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Demeter S, Leslie WD, Levin DP (2005) Radioactive iodine therapy for malignant and benign thyroid disease: a Canadian national survey of physician practice. Nucl Med Commun 26:613–621

    Article  PubMed  Google Scholar 

  2. McKenzie JM, Zakrij M, Sato A (1978) Humoral immunity in Graves’ disease. Clin Endocrinol Metab 7:31

    Article  PubMed  CAS  Google Scholar 

  3. Maxon HR, Thomas SR, Saenger EL, et al (1977) Ionizing irradiation and induction of clinically significant disease in human thyroid. Am J Med 63:967

    Article  PubMed  CAS  Google Scholar 

  4. Sofa AM, Skillern PG (1975) Treatment of hyperthyroidism with a large initial dose of sodium iodide I-131. Arch Intern Med 135:673

    Article  Google Scholar 

  5. Woeber KA (2000) Update on the management of hyperthyroidism and hyopothyroidism. Arch Intern Med 160:1067–1071

    Article  PubMed  CAS  Google Scholar 

  6. Hamburger JI (1980) Evaluation of toxicity in solitary non-toxic autonomously functioning thyroid nodules. J Clin Endocrinol Metab 50:1089–1093

    PubMed  CAS  Google Scholar 

  7. Peter HJ, Studer H, Forster T, Herber H (1982) The pathogenesis of “hot” and “cold” follicle in multinodular goiters. J Clin Endocrinol Metab 55:941–946

    Article  PubMed  CAS  Google Scholar 

  8. Ginsberg J (2003) Diagnosis and management of Graves’ disease. CMAJ 168:575–585

    PubMed  Google Scholar 

  9. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al (1998) Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Eng J Med 338:73–78

    Article  CAS  Google Scholar 

  10. Reid JR, Wheeler SF (2005) Hyperthyroidism: diagnosis and treatment. Am Famil Physician 72:623–630

    Google Scholar 

  11. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab 90:5321–5323

    Article  PubMed  CAS  Google Scholar 

  12. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al (1998) Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Eng J Med 338:73–78

    Article  CAS  Google Scholar 

  13. Maxon HR, Thomas SR, Chen IW (1981) The role of nuclear medicine in the treatment of hyperthyroidism and well differentiated thyroid adenocarcinoma. Clin Nucl Med 6:87–98

    Article  Google Scholar 

  14. Sankar R, Sekhri T, Sripathy G, Walia RP, Jain SK (2005) Radioactive iodine therapy in Graves’ hyperthyroidism: a prospective study from a tertiary referral center in North India. J Assoc Physicians India 53:603–606

    PubMed  CAS  Google Scholar 

  15. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA (2001) Radioiodine treatment of hyperthyroidism. Prognostic factors for outcome. J Clin Endocrinol Metab 86:3611–3617

    Article  PubMed  CAS  Google Scholar 

  16. Weetman AP (2000) Graves’ disease. N Engl J Med 343:1236–1248

    Article  PubMed  CAS  Google Scholar 

  17. Terrier P, Sheng ZM, Schlumberger M, et al (1988) Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas. Oncogene 2:403

    Google Scholar 

  18. Lemoine NR, Mayall ES, Wyllie FS, et al (1988) Activated ras oncogenes in human the thyroid cancers. Cancer Res 48:44–59

    Google Scholar 

  19. Atay-Rosenthal S (1999) Controversies on treatment of well-differentiated thyroid carcinoma and factors influencing prognosis. In: Freeman L (ed) Nuclear medicine annual. Lippincott, Williams and Wilkins, Philadelphia, pp 303–334

    Google Scholar 

  20. Beierwaltes WH (1978) The treatment of thyroid carcinoma with radioiodine. Semin Nucl Med 8:79

    Article  PubMed  CAS  Google Scholar 

  21. Rosario PW, Barroso AL, Rezende LI, Padrao EL, Fagundes TA, Reis JS, Purisch S (2005) Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer. Ann Nucl Med 19:247–250

    PubMed  Google Scholar 

  22. Kolfuerest S, Igerc I, Lind P (2005) Recombinant human thyrotropin is helpful in the follow up and I-131 therapy of patients with thyroid cancer: A report of the results and benefits using recombinant thryrotropin in clinical routine. Thyroid 15:371–376

    Article  Google Scholar 

  23. Intenzo CM, Jabbour S, Dam HQ, Capuzzi DM (2005) Changing concepts in the management of differentiated thyroid cancer. Semin Nucl Med 35:257–265

    Article  PubMed  Google Scholar 

  24. Fujie S, Okumura Y, Sato S, Akaki S, Katsui K, Himei K, Takemoto M, Kanazawa S (2005) Diagnostic capabilities of I-131, Tl-201, and Tc99m MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy. Acta Medica Okayama 59:99–107

    PubMed  Google Scholar 

  25. Ferreira SH, Lorenzethi BB, Bristow AF, et al (1988) Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 334:698–700

    Article  PubMed  CAS  Google Scholar 

  26. Poulson HS, Nielsen OS, Klee M, et al (1989) Palliative irradiation of bone metastases. Cancer Treatment Rev 16:41–48

    Article  Google Scholar 

  27. Tong D, Gillick L, Hendrickson FR (1982) Palliation of symptomatic osseous metastases. Cancer 50:893–899

    Article  PubMed  CAS  Google Scholar 

  28. Salazar OM, Rubin P, Hendrickson FR et al (1986) Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. Cancer 58:29–36

    Article  PubMed  CAS  Google Scholar 

  29. Bauman G, Charette M, Reid R, Sathya J (2005) Radiopharmaceuticals for the palliation of painful bone metastasis—a systemic review. Radiother Oncol 75:258–270

    PubMed  CAS  Google Scholar 

  30. Pauwels EKJ, Stokkel MPM (2001) Radiopharmaceuticals for bone lesions imaging and therapy in clinical practice. Q J Nucl Med 45:18–26

    PubMed  CAS  Google Scholar 

  31. Giammarile F, Mognetti T, Resche I (2001) Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q J Nucl Med 45:78–83

    PubMed  CAS  Google Scholar 

  32. Patel BR, Flowers WM Jr (1997) Systemic radionuclide therapy with strontium chloride Sr-89 for painful skeletal metastases in prostate and breast cancer. Southern Med J 90:506–508

    CAS  PubMed  Google Scholar 

  33. Papatheofanis FJ (2000) Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain. J Nucl Med 41:1021–1024

    PubMed  CAS  Google Scholar 

  34. Ramamoorthy N, Saraswathy P, Das MK, Mehra KS, Ananthakrishnan M (2002) Production logistics and radionuclidic purity aspects of 153Sm for radionuclide therapy. Nucl Med Commun 23:83–89

    Article  PubMed  CAS  Google Scholar 

  35. Cameron PJ, Klemp PF, Martindale AA, Turner JH (1999) Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy. Nucl Med Commun 20:609–615

    Article  PubMed  CAS  Google Scholar 

  36. Maxon HR, Thomas S, Hertzberg VS, Schroder LE, Englaro EE, Samaratunga R, et al (1992) Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med 22:33–40

    Article  PubMed  Google Scholar 

  37. Han SH, De Klerk JM, Zonnenberg BA, Tan S, Van Rijk PP (2001) 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases. Q J Nucl Med 45:84–90

    PubMed  CAS  Google Scholar 

  38. Kucuk NO, Ibis E, Aras G, Baltaci S, Ozalp G, Beduk Y, Canakci N, Soylu A (2000) Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases. Ann Nucl Med 14:239–245

    PubMed  CAS  Google Scholar 

  39. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Cabahug CJ, D’Alessandro T (1995) Tin-117m (4+)-DTPA for palliation of pain from osseous metastases: a pilot study. J Nucl Med 36:725–929

    PubMed  CAS  Google Scholar 

  40. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Straub RF, Cabahug CJ, et al (1993) Biodistribution of Sn-117m DTPA for palliative therapy of painful osseous metastases. Radiology 186:279–283

    PubMed  CAS  Google Scholar 

  41. Bishayee A, Rao DV, Srivastava SC, Bouchet LG, Bolch WE, Howell RW (2000) Marrow-sparing effects of 117mSn-die-thylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med 41:2043–2050

    PubMed  CAS  Google Scholar 

  42. Blower PJ, Kettle AG, O’Doherty MJ, Coakley AJ, Knapp FF Jr (2000) 99mTc(V)DMSA quantitatively predicts 188Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Eur J Nucl Med 27:1405–1409

    Article  PubMed  CAS  Google Scholar 

  43. Krishnamurthy GT, Krishnamurthy S (2000) Radionuclides for metastatic bone pain pain palliation: a need for rational re-evaluation in the new millennium [comment]. J Nucl Med 41:688–691

    PubMed  CAS  Google Scholar 

  44. Hoskin PJ, Ford HT, Harmer CL (1989) Hemibody irradiation (HBI) for metastatic bone pain in two histologically distinct groups of patients. Clin Oncol R Coll Radiol 1: 67–69

    PubMed  CAS  Google Scholar 

  45. Fischer M (1998) I-131 therapy of neural crest tumors. Nucl Med Newslett (King Saud Univ) 5:9–10

    Google Scholar 

  46. Quilty PM, Kirk D, Bolger JJ, et al (1994) A comparison of the palliative effects of strontium-89 and external beamra radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33–40

    Article  PubMed  CAS  Google Scholar 

  47. Silberstein EB, Elgazzar AH, Kapilivsky A (1992) Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med 17:17–27

    Article  Google Scholar 

  48. Maxon HR, Thomas SR, Hertzberg VS, et al (1982) Rhenium-186 hydroxyethylidene diphosphorate for the treatment of painful osseous metastases. Semin Nucl Med 22:30–40

    Google Scholar 

  49. Elgazzar AH, Maxon HR (1993) Radioisotope therapy for cancer related bone pain. Imaging Insights 2:1–6

    Google Scholar 

  50. Windsor PM (2001) Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre’s 10-year experience. Clin Oncol (R Coll Radiol) 13:219–227

    CAS  Google Scholar 

  51. Dickie GJ, Macfarlane D (1999) Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol 43:476–47

    Article  PubMed  CAS  Google Scholar 

  52. Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, Maini CL (2001) Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 66:101–109

    Article  PubMed  CAS  Google Scholar 

  53. Kvinnsland Y, Skretting A, Bruland OS (2001) Radionuclide therapy with bone-seeking compounds: Monte Carlo calculations of dose-volume histograms for bone marrow in trabecular bone. Phys Med Biol 46:1149–1161

    Article  PubMed  CAS  Google Scholar 

  54. Gelfand MJ, Elgazzar AH, Kriss VM, et al (1994) Iodine-123 MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 35:1753–1757

    PubMed  CAS  Google Scholar 

  55. Paltiel HJ, Gelfand MJ, Elgazzar AH, Washburn LC, et al (1994) Neural crest tumorss: I-123 MIBG imaging. Radiology 190:117–121

    PubMed  CAS  Google Scholar 

  56. Hoefnagel CA, deKraner J, Voute PA, Valdes Olmos RA (1991) Preoperative I-131 MIBG therapy in the management of neuroblastoma (abstract). J Nucl Med 32:921

    Google Scholar 

  57. Hoefnagel CA, deKraner J, Valdes Olmos RA, Voute PA (1994) I-131 MIBG as a first time treatment in high risk neuroblastoma patients. J Nucl Med 15:712–717

    CAS  Google Scholar 

  58. Mastrangelo R, Lasorell A, Troncone L, et al (1991) I-131 metaiodobenzylguanidine in neuroblastoma patients. J Nucl Med 35:248–251

    Google Scholar 

  59. Sisson JC, Shapiro B, Beirwaltes WH, et al (1984) Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 25:197–206

    PubMed  CAS  Google Scholar 

  60. Hoefnagel CA (1991) Radionuclide therapy revisited. Eur J Nucl Med 18:408–431

    Article  PubMed  CAS  Google Scholar 

  61. Taal BG, Hoefnagel CA, Vables Olmos RA, Boot H, Beijen JK (1996) Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 14:1829–1839

    PubMed  CAS  Google Scholar 

  62. Prvulovich EM, Stein RC, Bomanji JB, et al (1998) Iodine-131 MIBG therapy of a patient with carcinoid liver metastases. J Nucl Med 39:1743–1745

    PubMed  CAS  Google Scholar 

  63. Press OW, Eary JF, Applelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Buchko GM, Fisher LD, Porter B, et al (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219–1224

    Article  PubMed  CAS  Google Scholar 

  64. Press OW, Eary JF, Applbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, et al (1995) Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336–340

    Article  PubMed  CAS  Google Scholar 

  65. De Nardo GL, De Nardo SJ, O’Grady LF, Levy NB, Adams GP, Mills SL (1990) Fractionated radioimmunotherapy of B-cell malignancies with I-131-Lym-1. Cancer Res 50:1014–1016

    Google Scholar 

  66. DeNardo GL, O’Donnell RT, Oldham RK, DeNardo SJ (1998) A revolution in the treatment of non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 13:213–223

    Article  Google Scholar 

  67. Deutsch E, Brodack JW, Deutsch KF (1993) Radiation synovectomy revisited. Eur J Nucl Med 20:1113–1127

    Article  PubMed  CAS  Google Scholar 

  68. Gschwend N (1989) Synovectomy. In: Kelly WN, Harris ED, Ruddy S, et al (eds) Textbook of rheumatology. WB Saunders, Philadelphia, pp 1934–1961

    Google Scholar 

  69. Heim M, Goshen E, Amit Y, Martinowitz U (2001) Synoviorthesis with radioactive yttrium in haemophilia: Israel experience. Haemophilia 7 (Suppl 2):36–39

    Article  PubMed  Google Scholar 

  70. Rodriguez-Merchan EC, Jimenez-Yuste V, Villar A, Quintana M, Lopez-Cabarcos C, Hernandez-Navarro F (2001) Yttrium-90 synoviorthesis for chronic haemophilic synovitis: Madrid experience. Haemophilia 7 Suppl 2: 34–35

    Article  PubMed  Google Scholar 

  71. Onetti CM, Guyierrez F, Hiba E, et al (1982) Synoviorthesis with P-32 colloid chromic phosphate in rheumatoid arthritis and hemophilia, clinical, histopathological and arthographic changes. J Rheumatol 9:229–238

    PubMed  CAS  Google Scholar 

  72. Rivard GE, Givard M, Belanger R, et al (1994) Synoviortheses with colloidal P-32 chromic phosphate for the treatment of hemophilic arthropathy. J Bone Joint Surg Am 76:482–487

    PubMed  CAS  Google Scholar 

  73. Jeong JM, Lee YJ, Kim YJ, Chang YS, Lee DS, Chung JK, Song YW, Lee MC (2000) Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid. Appl Radiat Isotopes 52:851–855

    Article  CAS  Google Scholar 

  74. Siegel ME, Siegel HJ, Luck JV Jr (1997) Radiosynovectomy’s clinical applications and cost effectiveness: A review. Semin Nucl Med 28:364–371

    Article  Google Scholar 

  75. Ofluoglu S, Schwameis E, Zehetagruber I, Havlic E, Wanivenhaus A, Schweeger I, Weiss K, et al (2002) Radiation synovectomy with Ho-166-ferric hydroxide: A first experience. J Nucl Med 43:1489–1494

    PubMed  CAS  Google Scholar 

  76. Fischer M, Modder G (2002) Radionuclide therapy of inflammatory joint disease. Nucl Med Commun 23:829–831

    Article  PubMed  Google Scholar 

  77. Hauss F (1992) Radiosynoviorthese in der Orthopadie. Akt Rheumatol 17:64–66

    Article  Google Scholar 

  78. Paijit Asavatanabodee, et al (1997) Yttrium-90 radiochemical synovectomy in chronic knee synovitis: a one year retrospective review of 133 treatment interventions. J Rheumatol 24:639–642

    PubMed  CAS  Google Scholar 

  79. Deutsch E, et al (1993) Radiation synovectomy revisited. Eur J Nucl Med 20:1113–1127

    Article  PubMed  CAS  Google Scholar 

  80. Kresnik E, Mikososch P, Gallowitsch HJ, Jesenko R, Just H, Kogler D, Gasser J, Heinisch M, Unterweger O, Kumnig G, Gomez I, Lind P (2002) Clinical outcome of radiosynov thesis: a meta-analysis including 2190 treated joints. Nucl Med Commun 23:683–688

    Article  PubMed  CAS  Google Scholar 

  81. Jong M, Kwekkeboom D, Volkema R, Krenning ER (2003) Radiolabelled peptides for tumor therapy: current status and future directions. Eur J Nucl Med 30:463–469

    Article  CAS  Google Scholar 

  82. Capello A, Krenning E, Bernard B, Reubi J, Beerman W, de Jong M (2005) In-111-labelled somatostatin analogues in a rat tumour model: som atostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Biol 32:1288–1295

    Article  CAS  Google Scholar 

  83. Mazzaferi E (1997) Thyroid remnant I-131 ablation for papillary and follicular thyroid carcinoma. Thyroid 7:265–271

    Article  Google Scholar 

  84. Bruland OS, Skretting A, Solheim OP, Aas M (1996) Targeted radiotherapy of osteosarcoma using 153Sm-EDTMP. A new promising approach. Acta Oncologica 35:381–384

    PubMed  CAS  Google Scholar 

  85. Franzius C, Bielack S, Sciuk J, Vollet B, Jurgens H, Schober O (1999) High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nucl Medizin 38:337–340

    CAS  Google Scholar 

  86. Aas M, Moe L, Gamlem H, Skretting A, Ottesen N, Bruland OS (1999) Internal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP). Clin Cancer Res 5(10 Suppl):3148s–3152s

    PubMed  CAS  Google Scholar 

  87. Boyouth JE, Macey DJ, Kasi LP, et al (1995) Pharmacokinetics, dosimetry and toxicity of holmium-166 DOTMP for bone marrow ablation multiple myeloma. J Nucl Med 36:730–737

    Google Scholar 

  88. Rajendran JG, Eary JF, Bensinger W, Durack LD, Vernon C, Fritzberg A (2002) High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics biodistribution, and absorbed dose estimation. J Nucl Med 43:1383–1390

    PubMed  CAS  Google Scholar 

  89. Alexanan R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484–489

    Article  Google Scholar 

  90. Barlogie B, Alexanian R, Dick KA, et al (1987) High dose chemotherapy and autologous bone marrow transplantation for resistant myeloma. Blood 70:869–872

    PubMed  CAS  Google Scholar 

  91. Hoefnagel CA (1988) Radionuclide cancer therapy. Ann Nucl Med 12:61–70

    Article  Google Scholar 

  92. Srivastava S, Dadachova E (2001) Recent advances in radionuclide therapy. Semin Nucl Med 31:330–341

    Article  PubMed  CAS  Google Scholar 

  93. Geldof AA, van den Tillaar PL, Newling DW, Teule GJ (1997) Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model. Urology 49:795–801

    Article  PubMed  CAS  Google Scholar 

  94. Sundram FX, Yu SWK, Jeong JM, Somanesan S, Premaraj J, Saw MM, et al (2001) 188 Rhenium-TDD-lipiodol treatment of inoperable primary hepatocellular carcinoma—a case report. Ann Acad Med Singapore 30:542–545

    PubMed  CAS  Google Scholar 

  95. Keng G, Sundram FX, Yu S, Somanesan S, Premaraj, Oon CJ et al. (2002) Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radioconjugates. Ann Acad Med Singapore 31:3

    Google Scholar 

  96. Jong JM, Kim YJ, Lee YS, KO Jl, Son M, Lee DS, et al (2001) Lipiodol solution of a lipophilic agent, Re-188 TDD for the treatment of liver cancer. Nucl Med Biol 28:197–204

    Article  Google Scholar 

  97. Buscombe JR, Padhy AK (2001) Treatment of hepatocellular carcinoma: a pivotal role for nuclear medicine? Nucl Med Commun 22:119–120

    Article  PubMed  CAS  Google Scholar 

  98. Sundram FX, Jiomg JM, Zanzonico P, Bernal P, Chau T, Onkhuudai P, Divgi C, Knapp FF Jr, Padhy AK (2002) Trans-arterial rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma—results of a multicentre phase-1 study. World J Nucl Med 1:5–11

    Google Scholar 

  99. Padhy AK, Bernal P (2001) A CD Rom on the preparation of Re-188 Lipiodol (Perth, Australia, April, 2001)

    Google Scholar 

  100. Sundram F, Chau TC, Onkhuudai P, Bernal P, Padhy AK (2004) Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Mol Imaging 31:250–257

    Article  CAS  Google Scholar 

  101. Valdes Olmos RA, Hoefnagel CA (2004) Radionuclide therapy in oncology: the drawing of its concomitant use with other modalities? Eur J Nucl Med Mol Imaging 31:929–931

    PubMed  Google Scholar 

  102. Bodey RK, Flux GD, Evans PM (2003) Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm 18:89–97

    Article  PubMed  CAS  Google Scholar 

  103. Logothetis C, Tu S, Navone N (2003) Targeting prostate cancer bone metastases. Cancer 07:758–788

    Google Scholar 

  104. Tu SM, Millikan RE, Menigistu B, et al (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 357:336–341

    Article  PubMed  CAS  Google Scholar 

  105. Sciuto R, Festa A, Rea S, et al (2002) Effects of low dose cisplatin on Sr-89 therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43:79–86

    PubMed  CAS  Google Scholar 

  106. Horning SJ (2003) Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol 30 (Suppl 17):29–34

    Article  PubMed  CAS  Google Scholar 

  107. Press OW, Unger JM, Braziel RM, et al (2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated non Hodgkin’s lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606–1612

    Article  PubMed  CAS  Google Scholar 

  108. Mastrangelo S, Tornesello A, Diociaiuti L, et al (2001) Treatment of advanced neuroblastoma; feasibility and therapeutic potential chemotherapeutic potential of a novel approach combining I-131-MIBG and multiple drug chemotherapy. Br J Cancer 84:460–464

    Article  PubMed  CAS  Google Scholar 

  109. Yanik GA, Levine JE, Matthay KK, et al (2002) Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20:2142–2149

    Article  PubMed  CAS  Google Scholar 

  110. Grana C, Chinol M, Robertson C, et al (2002) Pretargeted adjunct radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207–212

    Article  PubMed  CAS  Google Scholar 

  111. Bodey RK, Evans PM, Flux GD (2005) Targeted radionuclide therapy. Spatial aspects of combined modality radiotherapy. Radiother Oncol 77:301–309

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Abdelhamid H. Elgazzar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdullatif Al-Bader
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Faculty of Medicine Kuwait University Health Sciences Center, PO Box 24923, 13110, Safat, Kuwait

    Abdelhamid H. Elgazzar MD, FCAP (Diplomate, American Board of Pathology Diplomate, American Board of Nuclear Medicine Professor and Chairman) (Diplomate, American Board of Pathology Diplomate, American Board of Nuclear Medicine Professor and Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Elgazzar, A.H., Al-Bader, A. (2006). Basis of Therapeutic Nuclear Medicine. In: Elgazzar, A.H. (eds) The Pathophysiologic Basis of Nuclear Medicine. Springer, Berlin, Heidelberg . https://doi.org/10.1007/978-3-540-47953-6_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-47953-6_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-23992-5

  • Online ISBN: 978-3-540-47953-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation